Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sarah Goldberg MD, MPH

Sarah B. Goldberg MD, MPH

Associate Professor of Medicine (Medical Oncology), Yale School of Medicine/Yale Cancer Center, New Haven, Connecticut

Dr. Sarah Goldberg is an Associate Professor of Medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center. She specializes in the treatment of thoracic malignancies, including lung cancer, mesothelioma, and thymoma. Her research interests include personalized medicine and immunotherapy for non–small cell lung cancer and identification of biomarkers that predict response to treatment.

Disclosures

  • Research Funding: AstraZeneca; Boehringer Ingelheim; Mirati
  • Advisory Board and Consultancy: AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Amgen; Blueprint Medicines; Sanofi Genzyme; Daiichi-Sankyo; Takeda; Janssen; Summit Therapeutics; Merck; Regeneron

Recent Contributions to PracticeUpdate:

  1. 2022 Top Story in Oncology: Nivolumab Plus Chemotherapy for Resectable NSCLC
  2. ESMO 2022: Recommendations From Dr. Sarah Goldberg for Lung Cancer
  3. Neoadjuvant Chemotherapy for Stage III NSCLC
  4. Updated Data From Amivantamab and Lazertinib in Progressive EGFR-Mutated Lung Cancer
  5. Adagrasib for Patients With Advanced KRAS G12C Mutated Lung Cancer
  6. ASCO 2022: Abstract Recommendations From Dr. Sarah Goldberg for Lung Cancer
  7. 2021 Top Story in Non–Small Cell Lung Cancer: IMpower010
  8. Trastuzumab Deruxtecan in HER2-Mutant NSCLC
  9. Poziotinib in HER2 Exon 20–Mutant NSCLC
  10. ESMO 2021: Recommendations From Dr. Sarah Goldberg

Most Read This Week

Recently Updated